It would be hard to believe that the Phase III 1250 person trial data was bad. Why it is being held off the market is still a mystery to me as it is counting not side effect profiles and drug interactions. The trial ended March 2017.
Nothing XXII does or announces will greatly benefit the stock until such time as the FDA acts. The Russell index inclusion is a temporary lift and the Anandia matter a great coup. However, we are still a partner away in all three areas, especially tobacco. I suspect we will be hearing soon on the iQOS application from PM which should be sent back for clinical testing. The news on non-combustible tobacco products is anything but uplifting. I suspect that one tobacco company will finally get religion and start testing our product with their flavoring. MO bought 200 cartons of our Spectrum cigarettes last year and I suspect BTI and PM have both used our VLN products.
The next 3-6 months all hinge on the FDA. Big tobacco will get a good idea of the FDA plans before we do or the market does ( the old leaky government ) and I suspect a move by them will be this year. If iQOS gets rejected and JUUL is made to do clinical trials a lot will change quickly.
Market Data 
Markets 
AI
